Christine Bojanowski, MD
Internal Medicine · la Jolla, CANPI 1679898506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Gilead at 24.3% of the total. Reporting peaked in 2019 at $196 and has fallen 81.1% since, to $37 in 2025.
Across 25 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$127
- Chiesi USA, Inc.$96
- Advanced Respiratory, Inc$68
- Sumitomo Pharma America, Inc.$62
- Baxter Healthcare$61
- Merz North America, Inc.$30
- plus $78 from 4 others
Across 2 payments — averaging $64,713 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$129K
What the payments were for
- Food & beverage$47090%
- Education$214%
- Gifts$306%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $127 |
| Chiesi USA, Inc. | 5 | $96 |
| Advanced Respiratory, Inc | 3 | $68 |
| Sumitomo Pharma America, Inc. | 1 | $62 |
| Baxter Healthcare | 2 | $61 |
| Merz North America, Inc. | 1 | $30 |
| United Therapeutics Corporation | 1 | $22 |
| AstraZeneca | 1 | $20 |
| Electromed, Inc. | 2 | $19 |
| Pulmonx Corporation | 1 | $17 |
How this compares
$521 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,004 |
| Azithromycin | 13 | $310 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in la Jolla
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fouad Moawadla Jolla$725K
- Lewis Rubinla Jolla$265K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.